Generic AI Is a Commodity
Any healthcare company can buy access to the same foundation models. When your competitors are using the same underlying AI on the same types of data, you are not differentiating — you are commodifying.
Generic AI knows that diabetes exists, what HbA1c is, and roughly how insulin works. Fine-tuned AI knows what that looks like in your specific patient population — and produces results no generic model can replicate.
Any healthcare company can buy access to the same foundation models. When your competitors are using the same underlying AI on the same types of data, you are not differentiating — you are commodifying.
Fine-tuned AI trained on your clinical data, your patient population, your operational patterns produces capabilities a competitor cannot replicate without access to the same proprietary data and the same tuning process.
A model that has learned the patterns in your specific context — your EHR terminology, your care pathways, your disease prevalence — is not just technically impressive. It is clinically useful in ways a generic model never will be.
Measurable, documented, defensible results — across every dimension of clinical AI. Drag, click a card, or use the dots to explore each dimension.
The fine-tuned model, the training pipeline, the validation framework, the monitoring infrastructure. Proprietary assets that a competitor cannot access without going through the same process.
Start a ConversationFine-tuned AI makes the most difference when your competitive advantage depends on the quality of your AI outputs — and when you have proprietary data that a generic model has never seen.
Your product competes on the quality of its AI outputs. Fine-tuned models that outperform generic alternatives on clinical tasks are a genuine product differentiator — visible to your users, measurable in your outcomes data, and defensible against competitors using off-the-shelf models.
Your member population, your provider network, and your claims patterns are proprietary. Fine-tuned AI that learns those patterns produces better risk stratification, better fraud detection, and better care management outputs than any model trained on general data.
Your patient population, your clinical workflows, and your operational patterns are specific to your organisation. AI tuned to those specifics will outperform generic AI on the tasks that matter most — documentation, risk stratification, operational forecasting.
If AI is central to your value proposition, the quality of that AI is your competitive moat. Fine-tuned models are harder to replicate and produce better results than foundation models used out of the box — and the gap grows as your data grows.
Generic models for generic problems. Fine-tuned models for the specific clinical and operational realities of your organisation.
Start a Conversation
100 Fastest Growth Companies
Global Spring Winner
Top App Development Company
AWS Partner Network
Google Cloud Partner
Highly Rated on Trustpilot
Verified Agency
Top App Development Company
ASSOCHAM Member
It depends on the task. Some fine-tuning approaches work well with relatively small, high-quality datasets. Others require larger volumes. We assess what you have during discovery and recommend the approach that will produce the best results given your data reality — which sometimes means a different technique than fine-tuning, and sometimes means a data augmentation strategy before tuning.
Patient data is de-identified before it is used in any training process, in compliance with HIPAA and applicable Indian data privacy regulations. De-identification is handled by us or in collaboration with your compliance team, and the process is documented for your regulatory records.
We run head-to-head evaluations on held-out clinical cases — comparing the fine-tuned model's outputs to the generic model's outputs, evaluated against clinical accuracy criteria defined with your subject matter experts. The improvement is measurable and documented before deployment.